Adicet Therapeutics Inc

Rhythm Pharmaceuticals, Inc., based in Boston, MA, is a global biopharmaceutical company dedicated to transforming the lives of patients with rare neuroendocrine diseases. The company focuses on advancing care and precision medicines that address the root causes of conditions such as hyperphagia and obesity. Committed to a community-centered approach, Rhythm Pharmaceuticals envisions a world where patients and their families can live their fullest lives through optimal, stigma-free care. Their innovative pipeline includes treatment options tailored for individuals with unique medical needs, highlighting their passion for helping patients thrive. Generated from the website

Gelesis is a biotechnology company based in Boston, MA, specializing in the development of innovative therapies for gastrointestinal (GI)-related chronic diseases. Their unique approach involves the use of superabsorbent hydrogels that mimic the properties of raw vegetables, which are administered in capsule form to act locally in the stomach and intestines. Their portfolio includes an FDA-cleared product, Plenity, designed to aid in weight management, as well as potential therapies in development for Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH), and Functional Constipation. Gelesis' hydrogel technology platform offers a safe and convenient alternative for individuals seeking weight management solutions without resorting to surgery or stimulants. By increasing the volume and firmness of consumed foods while reducing caloric density, their products help empower people to improve their diet, lifestyle, and overall health. With a focus on biomimicry and utilizing naturally-derived building blocks, Gelesis is at the forefront of developing groundbreaking treatments for GI-related chronic diseases.Generated from the website

Ironwood Pharmaceuticals, headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing and commercializing innovative therapies for individuals suffering from gastrointestinal and rare diseases. The company is recognized for its pioneering work on LINZESS, a leading prescription treatment for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation, as well as its ongoing research into apraglutide for short bowel syndrome patients. Founded in 1998, Ironwood Pharmaceuticals places a strong emphasis on patient-centered research and development, aiming to alleviate the burden of gastrointestinal diseases and address significant unmet medical needs. With a commitment to innovation, the company strives to improve the quality of life for millions of patients affected by these conditions. Generated from the website